<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395353</url>
  </required_header>
  <id_info>
    <org_study_id>16916</org_study_id>
    <secondary_id>F1J-JE-HMHF</secondary_id>
    <secondary_id>1702A3632</secondary_id>
    <nct_id>NCT03395353</nct_id>
  </id_info>
  <brief_title>A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder</brief_title>
  <official_title>A Long-term Safety Study of Duloxetine Hydrochloride in the Treatment of Japanese Children and Adolescents With Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this long-term study is to evaluate the safety and efficacy of duloxetine
      hydrochloride in Japanese children and adolescents with depressive disorder.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">July 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Any Adverse Events (AEs)</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Percentage of participants with any AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Any Adverse Reactions (ADRs)</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Percentage of participants with any ADRs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Any Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Percentage of participants with any SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Children's Depression Rating Scale-Revised (CDRS-R)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline on the CDRS-R</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Clinical Global Impression-Severity of Illness (CGI-S)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline on the CGI-S</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Trough Concentration of Duloxetine</measure>
    <time_frame>Week 4 through Week 50</time_frame>
    <description>PK: Trough Concentration of Duloxetine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Duloxetine hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine hydrochloride administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine Hydrochloride</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Duloxetine hydrochloride</arm_group_label>
    <other_name>LY248686</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  a) Participants extended from B058(1701A3631) study.

          -  b) New participants.

        Inclusion Criteria

          -  a) Participants who have completed 7 weeks of dosing in the B058(1701A3631) study and
             give signed informed consent to continue duloxetine administration in this study.

          -  b) Participants diagnosed with Major Depressive Disorder or persistent depressive
             disorder and completely meet the criteria of major depressive episode as defined by
             the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) with
             the Mini International Neuropsychiatric Interview for Children and Adolescents
             (MINI-KID) ver.7.0.2.

          -  b) Participants whose incipient age of depression was ≥7 years old.

        Exclusion Criteria:

          -  a, b) Have a current or previous diagnosis (DSM-5) of the following as judged by the
             investigator:

               -  Neurodevelopmental disorders

               -  Schizophrenia spectrum and other psychotic disorders

               -  Bipolar and related disorders

               -  Trauma and stressor-related disorders

               -  Disruptive · Impulse Control · and Conduct disorders

          -  a, b) Have a current diagnosis (DSM-5) of the following as judged by the investigator:

               -  Obsessive-compulsive and related disorders

               -  Anorexia nervosa, Bulimia nervosa, Binge-eating disorder

               -  Sleep-wake disorders

               -  Neurocognitive disorders

               -  Disruptive mood dysregulation disorder

          -  a, b) Have personality disorders, in the judgment of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shionogi</name>
      <address>
        <city>Osaka</city>
        <zip>541-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

